16 Jul 2014, BioSpectrum Bureau , BioSpectrum
Singapore: In a bid to launch overseas and to expand its Australian operations, Brisbane-based personalised medicine start-up DoseMe has secured $500,000 in investment funding.
The company is said to be marketing a proprietary software technology designed to allow clinicians to prescribe medicines based on a patient's individual ability to absorb, process and clear a drug.
A report said that it uses simple information including a patient's height, weight and gender to generate complex treatment algorithms based on Bayesian dosing principles.
The software is also said to then incorporate patient-specific lab results and continues to learn and adjust doses over time.
Currently supporting 13 medications across four therapeutic areas, DoseMe software is available via mobile devices, a web-based application and as a module to integrate into patient management software. The therapeutic areas include anti-microbial, chemotherapy, anti-coagulants and pro-coagulants.
The company said in a statement that, "In trials, the software has been shown to be almost twice as effective as traditional dosing methods."
Dr Robert McLeay, co-founder and technical director, DoseMe said that funds from this and future capital raisings will be put towards scaling up the company's operations. "We now have hospitals, pharmacies and individual doctors using the system in Queensland, Western Australia and Victoria. Future investment rounds will be used to help us scale our business by expanding the product to new medications and also to roll out DoseMe to further international markets," he added.